TGF-beta, a FOXP3 + Treg cells inducer for suppression of alloimmune response
It has been well-known for a while that TGF-beta is a potent immunosuppressive cytokine with multiple suppressive actions on a variety of immune cells including T cells, B cells, macrophages, and other cells, and acts with some other inhibitory molecules to maintain a state of immune tolerance in peripheral tissues (Prud'homme and Piccirillo, 2000) . Mice with homozygous for Tgfb1 gene mutation die due to a massive multifocal mixed inflammatory cell infiltration and tissue necrosis in numerous organs (Shull et al., 1992; Christ et al., 1994) through autoimmune responses, such as antibody deposit in renal glomeruli (Yaswen et al., 1996) . However, the cellular mechanisms by which TGF-beta suppresses immune responses are not fully understood. Recent findings suggest that TGF-beta is required for regulatory T (Treg) cell development; TGF-beta induces FOXP3 (forkhead box P3) expression in nonregulatory CD4 + CD25 -T cells, and consequently converts these cells to CD4 + CD25 + FOXP3 + Treg cells in vitro (Chen et al., 2003) , and in vivo is required for expansion of this phenotype of Treg cells (Peng et al., 2004) . TGF-beta-dependent FOXP3 + Treg cells, including both CD4 + and CD8 + phenotypes, can induce immune tolerance to allografts in animal models (Cobbold et al., 2004; Kapp et al., 2006) . However, it is also suggested that in the presence of IL-6, TGF-beta induces differentiation of naïve CD4 + T cells to effector interleukin (IL)-17producing Th17 cells (Bettelli et al., 2006; Veldhoen et al., 2006) , but the evidence for TGFbeta-dependent Th17 cell development in vivo has not been confirmed yet. Indeed, recent studies suggest that TGF-beta does not directly stimulate Th17 cell differentiation, instead it inhibits Th1 cells development that indirectly favors Th17 cell expansion (Santarlasci et al., 2009) , and Th17 cells can be generated in the absence of TGF-beta signaling (Ghoreschi et al., 2010) . Thus, TGF-beta may not have any direct effect on effector Th17 cells, and it may only act as an immuno-down regulatory cytokine by its induction of FOXP3 + Treg cell as well as directly and indirectly in the suppression of other types of immune cells. The positive correlation of TGF-beta expression at early phase of transplantation with kidney transplant survival has reported in literature. A higher level of TGF-beta in the biopsies within 6 months of transplantation or during acute rejection episodes is associated with a decreased risk of chronic rejection development (Eikmans et al., 2002) , and better graft function (Ozdemir et al., 2005) . In the early antibody-mediated rejection, occurring within the first 3 weeks after transplantation, there is a strong correlation of intrarenal expression of TGF-beta 1 with FOXP3 mRNA, and importantly the low intrarenal TGF-beta 1 and FOXP3 have significantly shorter graft survival, implied by an increased risk for renal graft failure within next 12 months (Viklicky et al., 2010) . The beneficial effect of immunoregulatory TGF-beta on early survival of kidney transplants is further supported by a recent experimental study, demonstrating that only the early renal allograft acceptance is associated with TGF-beta-induced immune regulation, both peripherally by splenocytes as well as locally by graft-infiltrating cells (Cook et al., 2008) . All these studies may indicate that TGF-beta may benefit kidney transplant survival at the early phase of transplantation by its immunoregulatory activities, including induction of FOXP3-expressing Treg cells.
The adverse effects of TGF-beta on kidney transplant survival 3.1 TGF-beta, a fibrotic factor for chronic rejection of kidney transplants
Chronic rejection in kidney transplants is a major cause of long-term graft dysfunction and ultimate failure, and is characterized as a progressive process of interstitial fibrosis, tubular atrophy, and glomerulosclerosis and vascular sclerosis (Racusen et al., 1999; Nankivell et al., 2003) . Although the pathogenesis of chronic rejection is not fully understood, it is proposed that these pathologies may result from chronic repair response towards injurious and inflammatory stimuli. As a result, extracellular matrix (ECM) accumulates in functional tissue leading to successive tissue fibrosis in the vascular (vascular sclerosis), tubulointerstitium (interstitial fibrosis) and glomeruli (glomerulosclerosis), and the excessive interstitial fibrosis progressively consequently leads to tubular atrophy in kidney transplants. It has been reported that much of this ECM is produced by alpha-smooth muscle actin (alpha-SMA)-expressing myofibroblasts (Simonson, 2007; Wynn, 2008) , and early presence of alpha-SMA expression predicts the progression toward pathologic changes for chronic rejection in kidney transplants (Badid et al., 2002; Hertig et al., 2008) , suggesting that myofibroblasts are the primary effector cells for chronic rejection of kidney transplants. Numerous studies have reported a significant correlation of the up-regulation of intragraft TGF beta 1 and active plasma TGF-beta 1 with chronic rejection in kidney transplants (Sharma et al., 1996; Ozdemir et al., 2005; Harris et al., 2007; Del Prete et al., 2009 ) and with cyclosporine A (CsA) toxicity (Ozdemir et al., 2005) . In kidney cell cultures, in addition to the growth factors as discussed above, many injury or pro-inflammatory factors (e.g. platelet-activating factor, hydrogen peroxide, IL-1beta and TNF-alpha) and CsA induce TGF-beta 1 expression (Ruiz-Ortega et al., 1997; Iglesias-De La Cruz et al., 2001; Vesey et al., 2002a; Vesey et al., 2002b; Slattery et al., 2005; Guan et al., 2010) . Thus, TGF-beta has been considered as a fibrogenic cytokine, involved in fibrosis or chronic rejection of kidney transplants (Morris-Stiff, 2005) , and has been proposed as a therapeutic target for this problem (Mannon, 2006) . However, the pathways of fibrotic activity of TGF-beta in chronic rejection of kidney transplants are not completely understood. TGF-beta is a pivotal factor for the normal process of tissue homeostasis in every part of our body (Siegel and Massague, 2003) . Hence, it is easy to understand why TGF-beta is upregulated and involved in chronic tissue repair when kidney transplants are exposed to chronic inflammation/injury as well as nephrotoxicity of immunosuppressive drugs, but how TGF-beta-mediated chronic repair responses leads to the pathologic changes of chronic rejection in kidney transplants is not exactly known. It has been documented that epithelial-tomesenchymal transition (EMT) can be induced by TGF-beta and is considered as a continuous supply to myofibroblast population during the progression of renal fibrosis (Iwano, 2010) . Indeed, EMT has been detected in kidney transplant biopsies with chronic rejection but not in those with stable function (Vongwiwatana et al., 2005) . However, recent experimental studies demonstrates that in the kidneys with unilateral ureteral obstruction a large majority of myofibroblasts for kidney fibrosis actually comes from the phenotypic transition of existing normal interstitial fibroblasts, whereas there is no evidence indicating that epithelial cells migrate outside of the tubular basement membrane and differentiate into interstitial myofibroblasts or EMT (Humphreys et al., 2010) , and overexpression of TGF-beta 1 in renal TECs induces fibrosis in the kidney that is associated with interstitial fibroblast proliferation but not with EMT (Koesters et al., 2010) . This notion may be also applied to the chronic rejection of kidney transplants that remains further elusive. At the molecular level, TGF-beta stimulates ECM production and/or inhibits ECM degradation in various kidney cells including TECs, interstitial fibroblasts and mesanglial cells (Ruiz-Ortega et al., 1997; Iglesias-De La Cruz et al., 2001; Bottinger and Bitzer, 2002; Vesey et al., 2002a; Vesey et al., 2002b; Tian et al., 2006; Huang et al., 2008) . All these data suggest that the fibrotic effect of TGF-beta in the chronic rejection of kidney transplants may be mediated simply by its stimulation of fibroblast growth and ECM remodeling leading to ECM accumulation or fibrosis. Fig. 1 . A simple scheme for cellular pathways of TGF-beta in renal repair/regeneration, immune-modulation and renal fibrosis in kidney transplants.
Following ischemia-reperfusion injury, renal tubular epithelial cells and other types of renal cells are programmed to death (apoptosis and necrosis). TGF-beta may protect cells from apoptosis and stimulate proliferation of surviving renal cells to repair or regenerate the damaged tissue of kidney transplants. When naïve T cells are primed by alloantigens from the kidney transplants, TGF-beta may induce the development of FOXP3 + Treg cells that suppress alloimmunity against the kidney transplants. However, chronic upregulation of TGF-beta production in the kidney transplants may induce ECM-producing myofibroblasts and chronic stimulation of cell growth of myofibroblasts in the tubulointerstitium, glomeruli and vascular tissue may result in chronic rejection, indicated by interstitial fibrosis, tubular atrophy, glomerulosclerosis, and vascular fibrosis. DC: dendritic cells; NT: naïve T cells; Th: T helper cells; B: B and plasma cells; CTL: CD8+ cytotoxic T cells.
Conclusion
TGF-beta affects kidney transplant survival in many ways; it is a growth factor for tissue regeneration and tissue remodeling when kidney transplants are damaged, and is an immunosuppressive factor when cellular immune response to kidney transplants is activated. At the beginning of transplantation, when kidney transplants are damaged by ischemia-reperfusion injury and recipient's immune response is activated, TGF-beta may repair kidney transplants by stimulation of tissue regeneration, protection of renal cells from apoptosis and negatively regulates cellular immune response to kidney transplants by induction of FOXP3 + Treg cells. Later on, when kidney transplants are attacked by chronic inflammation including drug-resistant immune response and virus infection, and nephrotoxicity of immune suppressive drugs, the chronic repair response of TGF-beta may induce tissue remodeling of kidney transplants leading to chronic rejection (Figure 1) . Thus, despite of the short-term beneficial effects of tubule-repairing and immune-down-regulation immediately posttransplantation, the long-term effects of TGF-beta on kidney transplant survival under current immune therapies seem to be negative as increased expression of TGF-beta1 promotes growth of fibroblasts and ECM accumulation leading to tissue remodeling in the tubulointerstitium, vascular tissue and glomeruli or chronic rejection.
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